Varespladib is primarily investigated for its potent inhibitory effect on secretory phospholipase A2 (sPLA2), an enzyme involved in inflammatory pathways. It has been studied in the context of acute inflammatory conditions, particularly in diseases where sPLA2 levels are elevated, such as sepsis and acute coronary syndrome. By blocking sPLA2 activity, varespladib reduces the production of pro-inflammatory mediators, which may help mitigate tissue damage and systemic inflammation. It has also shown potential in preclinical studies for snakebite envenomation. sPLA2 toxins are common in many snake venoms and contribute to tissue necrosis, myotoxicity, and systemic effects. Varespladib demonstrates broad-spectrum inhibition of these toxic enzymes across various snake species, making it a candidate for a universal adjunct treatment in snakebite, especially where antivenom access is limited. Additionally, research explores its use in chronic inflammatory diseases, including atherosclerosis, due to its ability to lower vascular inflammation markers. Though clinical development has faced challenges, its mechanism supports ongoing interest in both acute and chronic inflammatory conditions.